These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34558211)

  • 1. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
    Stefania Infante M; Fernández-Cruz A; Núñez L; Carpio C; Jiménez-Ubieto A; López-Jiménez J; Vásquez L; Del Campo R; Romero S; Alonso C; Morillo D; Prat M; Luis Plana J; Villafuerte P; Bastidas G; Bocanegra A; Serna Á; De Nicolás R; Marquet J; Mas-Ochoa C; Cordoba R; García-Suárez J; Comai A; Martín X; Bastos-Oreiro M; Seri C; Navarro-Matilla B; López-Guillermo A; Martínez-López J; Ángel Hernández-Rivas J; Ruiz-Camps I; Grande C;
    Cancer Med; 2021 Nov; 10(21):7629-7640. PubMed ID: 34558211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of infection associated with new therapies for lymphoproliferative syndromes.
    Los-Arcos I; Aguilar-Company J; Ruiz-Camps I
    Med Clin (Barc); 2020 Feb; 154(3):101-107. PubMed ID: 31771856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
    Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
    Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Vitale C; Salvetti C; Griggio V; Porrazzo M; Schiattone L; Zamprogna G; Visentin A; Vassallo F; Cassin R; Rigolin GM; Murru R; Laurenti L; Rivela P; Marchetti M; Pennese E; Gentile M; Boccellato E; Perutelli F; Montalbano MC; De Paoli L; Reda G; Orsucci L; Trentin L; Cuneo A; Tedeschi A; Scarfò L; Gaidano G; Mauro FR; Foà R; Boccadoro M; Coscia M
    Blood; 2021 Jun; 137(25):3507-3517. PubMed ID: 33651883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for anti-CD20 antibodies in CLL?
    Shah HR; Stephens DM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
    Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
    Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
    Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
    Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors.
    Mauro FR; Frustaci AM; Visentin A; Vitale C; Bartoletti M; Oltolini C; Zappulo E; Mikulska M
    Crit Rev Oncol Hematol; 2024 Sep; 201():104408. PubMed ID: 38880368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
    Xiang S; Shen R; Xiang J; Zhu N; Gu J; Shen J; Zhang Y; Ge H
    Expert Opin Drug Saf; 2024 May; 23(5):627-636. PubMed ID: 38456691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.